ArticleFrontiers in immunology2025
Establishment of rapid saturation mutagenesis and screening methods for improving the neutralizing activity of monoclonal antibodies.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Monoclonal antibodies have been widely used in the fight against infectious diseases and are recommended for postexposure prophylaxis (PEP) of the rabies virus because of their advantages of easy supply, low cost, and high efficacy. To maximize treatment efficiency and minimize side effects, the binding affinity of isolated mAbs requires further enhancement. Methods: In this study, we developed a high-throughput saturation mutagenesis platform to improve the neutralizing activity of a preclinical antirabies mAb. We generated a system displaying antibodies on mammalian cell surfaces to block the invasion of the pseudotyped rabies virus. Saturation mutagenesis was performed on the complementarity-determining regions (CDRs) of the parental mAb, followed by screening for mutant mAbs with greater neutralizing activity. Results: We identified several mutations, including S5A, K18F, and N29C, that increased the neutralizing activity of the mAbs against six fixed strains of rabies virus, with average improvements of 4.92, 3.45, and 4.99 times, respectively. Furthermore, mAbs with the combined mutations S4I-P35S-N76D and S14H-T32N demonstrated significantly improved neutralizing activity. Conclusion: We established a high-throughput saturation mutagenesis platform for antibody affinity modification, enhancing the anti-infection ability of the antirabies NC08 antibody through single-point and multiple-point mutants. This platform is also applicable for optimizing other mAbs in preclinical stages in terms of neutralizing activity and achieving broad-spectrum activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.